This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2025 Zacks Investment Research | 101 N Wacker Drive, Floor 15, Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.75% per year. These returns cover a period from January 1, 1988 through July 7, 2025. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
View All Zacks #1 Ranked Stocks
Zacks News
Pharma Stock Roundup: Q2 Earnings & J&J and PFE's Coronavirus Updates in Focus
by Kinjel Shah
Pfizer's (PFE) coronavirus vaccine candidate enters phase III. Several drugmakers announce second-quarter results.
Merck (MRK) Beats on Q2 Earnings, Misses Sales, Ups View
by Zacks Equity Research
Merck (MRK) increases earnings and sales guidance for the year, which pushes shares up in pre-market trading.
The Zacks Analyst Blog Highlights: AZN, UNP, MO, SAP and UBER
by Zacks Equity Research
The Zacks Analyst Blog Highlights: AZN, UNP, MO, SAP and UBER
AstraZeneca (AZN) Q2 Earnings & Sales Beat, Increase Y/Y
by Zacks Equity Research
AstraZeneca (AZN) comes up with better-than expected Q2 results. It maintains its financial outlook for the year. Stock up.
How Much Will Coronavirus Hurt Merck's (MRK) Q2 Earnings? (Revised)
by Zacks Equity Research
Investor focus is likely to be on the impact of the coronavirus outbreak on Merck's(MRK) performance when it reports second-quarter earnings.
Will Cigna (CI) Keep the Beat Streak Alive in Q2 Earnings?
by Zacks Equity Research
Cigna's (CI) business is likely to have been weighed down in Q2 due to high unemployment rate, partly offset by the delay in elective procedures resulting in lower claims.
Big Drug Stock Q2 Earnings on Jul 30: LLY, GILD, VRTX & More
by Kinjel Shah
Let us take a look at five big drug/biotech companies, GILD, LLY, VRTX, ALXN, and AZN, gearing up for their earnings release.
Top Stock Reports for AstraZeneca, Union Pacific & Altria
by Sheraz Mian
Today's Research Daily features new research reports on 16 major stocks, including AstraZeneca (AZN), Union Pacific (UNP) and Altria Group (MO).
Late-Stage Coronavirus Vaccine Trials Begin: Biotech ETFs to Gain
by Sweta Jaiswal, FRM
Two major vaccine developers' entrance into the final stage trials is expected to boost investor optimism.
Will Humira, Cancer Drugs Drive AbbVie (ABBV) Q2 Earnings?
by Zacks Equity Research
AbbVie's (ABBV) Q2 top-line results are expected to reflect the impact of coronavirus on sales of Humira, Imbruvica and Venclexta.
Coronavirus Vaccine Efforts Key to Novavax (NVAX) Q2 Earnings
by Zacks Equity Research
Novavax (NVAX) is developing a coronavirus vaccine. While increased clinical activity is expected to have increased expenses, pipeline development grants may have offered some respite in Q2 earnings.
Moderna (MRNA) to Report Q2 Earnings: What's in the Cards?
by Zacks Equity Research
Investors focus is likely to be on the progress of its pipeline candidates, especially coronavirus vaccine candidate, on the second-quarter earrings call.
How Much Will Coronavirus Hurt Merck's (MRK) Q2 Earnings?
by Zacks Equity Research
Investor focus is likely to be on the impact of the coronavirus outbreak on Merck's (MRK) performance when it reports second-quarter earnings.
COVID-19 Vaccine Push Brings Hope: Stock & ETF Beneficiaries
by Sanghamitra Saha
There are at least a hundred candidates in the COVID-19 vaccine race globally. However, few companies like Moderna, Pfizer and AstraZeneca are showing considerable hope.
Top Ranked Income Stocks to Buy for July 28th
by Zacks Equity Research
Here are four stocks with buy rank and strong income characteristics for investors to consider today, July 28th.
What's in Store for AstraZeneca (AZN) This Earnings Season?
by Zacks Equity Research
AstraZeneca's (AZN) second-quarter results are expected to reflect the impact of new drug sales. However, the impact of coronavirus pandemic remains to be seen.
Pharma Stock Roundup: NVS, RHHBY Earnings, AZN, PFE Coronavirus Vaccine Early Data
by Kinjel Shah
Pfizer (PFE) and AstraZeneca (AZN) announce early data on their coronavirus vaccine candidates. Novartis (NVS) and Roche (RHHBY) announce second-quarter results.
The Zacks Analyst Blog Highlights: AstraZeneca, BioNTech, Pfizer, Cimarex Energy, Diamondback Energy, Centennial Resource Development and Bonanza Creek Energy
by Zacks Equity Research
The Zacks Analyst Blog Highlights: AstraZeneca, BioNTech, Pfizer, Cimarex Energy, Diamondback Energy, Centennial Resource Development and Bonanza Creek Energy
Astrazeneca (AZN) Stock Sinks As Market Gains: What You Should Know
by Zacks Equity Research
Astrazeneca (AZN) closed the most recent trading day at $56.98, moving -1.88% from the previous trading session.
Biotech ETFs to Gain on Coronavirus Vaccine Progress
by Sweta Jaiswal, FRM
The race to find a coronavirus vaccine is heating up as the latest positive data from progress in trials are being published.
The Zacks Analyst Blog Highlights: AstraZeneca, Pfizer, Moderna, Vaxart and Novovax
by Zacks Equity Research
The Zacks Analyst Blog Highlights: AstraZeneca, Pfizer, Moderna, Vaxart and Novovax
EU Stimulus, Vaccine Hopes Aid Oil Price, Upstream Stocks Rise
by Kaibalya Pravo Dey
Significant gains in crude prices are likely to provide a profit-boosting opportunity to exploration and production companies.
3 Small Biotechs in Focus on Promising Coronavirus Vaccine Data
by Zacks Equity Research
Pfizer (PFE) and AstraZeneca (AZN) announce promising data from early-stage coronavirus vaccine studies. Here we discuss three leading biotechs with potential to recshare price gains.
Stock Market News for Jul 21, 2020
by Zacks Equity Research
U.S. stock markets closed higher on Monday as the tech rally resumed after the gap of a week.
The Zacks Analyst Blog Highlights: Netflix, AstraZeneca, Union Pacific, NextEra Energy and Estee Lauder
by Zacks Equity Research
The Zacks Analyst Blog Highlights: Netflix, AstraZeneca, Union Pacific, NextEra Energy and Estee Lauder